Research programme: anti-HIV therapies - Isis/ImQuest
Alternative Names: Combination topical microbicide product - ImQuest Biosciences; IQP-0831; ISIS-5320; NSC 665353Latest Information Update: 28 Jul 2020
At a glance
- Originator Isis Pharmaceuticals
- Developer ImQuest Life Sciences; Isis Pharmaceuticals
- Class Antivirals; Oligodeoxyribonucleotides; Thionucleotides
- Mechanism of Action HIV envelope protein gp120 inhibitors; HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 20 Jul 2020 ImQuest Life Sciences has been acquired by Cytocom
- 29 Mar 2012 No development reported - Preclinical for HIV infections (prevention) in USA (Topical)
- 06 Aug 2008 This programme is still in active preclinical development